drugset
drugset / Trial / NCT01949688

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors

NCT01949688 ↗

Phase 1/2 Completed 26 enrolled Shiga University Tokyo University · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

In this study, the investigators examine using a combination of two types of HLA-A\*2402 (or HLA-A\*0201)-restricted epitope peptides, which were derived from VEGF-R1 and VEGF-R2 the safety, immunogenicity, and antitumor effect of vaccine treatment for advanced solid tumor patients who are refractory to standard therapy.

Timeline

Start
2010-06
Primary completion
2019-03
Completion
2019-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HLA-A*2402 or A*0201 restricted peptides Vaccine — Subcutaneous

Indications

cancer